Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials∗ A.Michael Lincoff, MD, LeRoy A LeNarz, MD, George J Despotis,

Slides:

Advertisements

Similar presentations

Peter K. Smith, MD, Robert M. Califf, MD, Robert H

Advertisements

Elevated Hemoglobin A1c Is Associated With Lower Socioeconomic Position and Increased Postoperative Infections and Longer Hospital Stay After Cardiac.

The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary artery bypass surgery Madhav Swaminathan, MD,

Major Bleeding, Transfusions, and Anemia: The Deadly Triad of Cardiac Surgery Marco Ranucci, MD, FESC, Ekaterina Baryshnikova, BD, Serenella Castelvecchio,

Volume 66, Issue 2, Pages (August 2014)

Warfarin therapy does not increase bleeding in patients undergoing heart transplantation Cullen D Morris, MD, J.David Vega, MD, Jerrold H Levy, MD, Nancy.

Leena Khaitan, MD, Francis P Sutter, Scott M Goldman, MD

Elevated Hemoglobin A1c Is Associated With Lower Socioeconomic Position and Increased Postoperative Infections and Longer Hospital Stay After Cardiac.

Robert Brewer, MD, MHSA, Patricia F. Theurer, BSN, Chad M

Injury of the common peroneal nerve after cardiothoracic operations

Coronary artery bypass grafting in patients with advanced left ventricular dysfunction Gregory D Trachiotis, MD, William S Weintraub, MD, Thomas S Johnston,

James Edgerton, MD, Giovanni Filardo, PhD, MPH, William H

Cognitive deficit after aortic valve replacement

Monocyte Fc gamma receptor expression in patients undergoing coronary artery bypass grafting Demetrios C Stefanou, FRCS, George Asimakopoulos, FRCS,

Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting Carlos A Estrada, MD,

John H Braxton, MD, Charles A

Age of Transfused Red Cells and Early Outcomes After Cardiac Surgery

Functional assessment of disease-free saphenous vein grafts at redo coronary artery bypass grafting Thomas V Bilfinger, MD, James A Vosswinkel, MD, Christos.

Brent A Grishkin, MD, Robert A Helsel, MD

Atrial Fibrillation After Coronary Artery Bypass Grafting Surgery: Development of a Predictive Risk Algorithm Mitchell J. Magee, MD, Morley A. Herbert,

Robert E. Freundlich, MD, MS, Michael D. Maile, MD, MS, Mark M

Mini-sternotomy for off-pump coronary artery bypass grafting

Coronary artery operation in patients after breast cancer therapy

Theodore C Koutlas, MD, Joseph R Elbeery, MD, J

David C Charlesworth, MD, Donald S Likosky, PhD, Charles A

Emergency Coronary Artery Bypass Grafting Can Be Performed Safely Without Cardiopulmonary Bypass in Selected Patients Faraz Kerendi, MD, John D. Puskas,

Trends in Robotic-Assisted Coronary Artery Bypass Grafts: A Study of The Society of Thoracic Surgeons Adult Cardiac Surgery Database, 2006 to 2012 David.

Lu Dai, MSc, Stephanie L. Mick, MD, Keith R. McCrae, MD, Penny L

The Society of Thoracic Surgeons Mitral Valve Repair/Replacement Plus Coronary Artery Bypass Grafting Composite Score: A Report of The Society of Thoracic.

Milo Engoren, MD, Thomas A. Schwann, MD, Robert H. Habib, PhD, Sean N

Richard S. D’Agostino, MD, Jeffrey P

Coronary artery bypass on the beating heart with the Octopus: a North American experience1 Ted H Spooner, MD, Peter E Dyrud, MD, Bjorn K Monson, MD,

Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery Alan F Merry, FANZCA, Peter J Raudkivi, FRACS, Neil G Middleton, FCASA,

Carmelina Gurrieri, MD, James J. Butz, MD, Toby N

Left pleural effusion after coronary artery bypass decreases with a supplemental pleural drain Maryann Payne, MD, George J Magovern, MD, Daniel H Benckart,

Effects of Blood Transfusion on Cause-Specific Late Mortality After Coronary Artery Bypass Grafting—Less Is More Thomas A. Schwann, MD, Joseph R. Habib,

Zoe K. McQuilten, MBBS, Nick Andrianopoulos, MBBS, MBiostat, Erica M

Safety and efficacy of perioperative cell salvage and autotransfusion after coronary artery bypass grafting: a randomized trial Gavin J Murphy, MD, FRCS,

Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity Joseph C Cleveland, MD, A.Laurie W Shroyer, PhD, Anita Y Chen,

Pathology of the Radial and Internal Thoracic Arteries Used as Coronary Artery Bypass Grafts Eric Kaufer, BS, Stephen M Factor, MD, Rosemary Frame, MS,

Peter K. Smith, MD, Robert M. Califf, MD, Robert H

Benjamin C. Sun, MD, Timothy A. Dickinson, CCP, Eric A

Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: Clinical and economic outcomes Walter.

Impact of Residency Status on Perfusion Times and Outcomes for Coronary Artery Bypass Graft Surgery Constance K. Haan, MD, Sarah Milford-Beland, MS,

Red Blood Cell Transfusion Is Associated With Troponin Release After Elective Off- Pump Coronary Artery Bypass Surgery Fausto Biancari, MD, PhD, Eeva-Maija.

Mudassir I Dar, Timothy Gillott, Franco Ciulli, MD, Graham J Cooper

The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary artery bypass surgery Madhav Swaminathan, MD,

Limitations of Hospital Volume as a Measure of Quality of Care for Coronary Artery Bypass Graft Surgery Karl F. Welke, MD, Mitchell J. Barnett, PharmD,

Amiodarone as a First-Line Therapy for Postoperative Junctional Ectopic Tachycardia Lubica Kovacikova, MD, PhD, Nina Hakacova, MD, Dusan Dobos, MD, Peter.

Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery Scott B Chelemer, MD, B.Stephen Prato, MA, Paul.

Michael W. A. Chu, MD, Steve R. Wilson, BS, Richard J

Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair Greg Stratmann, MD, PhD, Isobel A Russell,

Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis

Bleeding Complications and Blood Product Utilization With Left Ventricular Assist Device Implantation Justin M. Schaffer, MS, George J. Arnaoutakis,

Trends in Patient Characteristics and Outcomes of Coronary Artery Bypass Grafting in the 2000 to 2012 Medicare Population Christian McNeely, MD, Stephen.

Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost Michael J Ray, PhD, Mark F O’Brien

Propensity score analysis of stroke after off-pump coronary artery bypass grafting Gary L Grunkemeier, PhD, Nicola Payne, MPhiL, Ruyun Jin, MD, John R.

Randomized Controlled Trial of Pericardial Blood Processing With a Cell-Saving Device on Neurologic Markers in Elderly Patients Undergoing Coronary Artery.

Measuring for improvement: from Toyota to thoracic surgery

Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit Michael J Ray, PhD, Majella M Hales,

Survival and Quality of Life for Nonagenarians After Cardiac Surgery

Red Blood Cell Transfusions Impact Pneumonia Rates After Coronary Artery Bypass Grafting Donald S. Likosky, PhD, Gaetano Paone, MD, MHSA, Min Zhang,

Sérgio A de Oliveira, MD The Annals of Thoracic Surgery

Similar neurobehavioral outcome after valve or coronary artery operations despite differing carotid embolic counts Michael J. Neville, MDa, John Butterworth,

Håvard Nordgaard, MD, Nicola Vitale, MD, PhD, Rune Haaverstad, MD, PhD

Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations William C Oliver, MD, Paula J Santrach, MD, Gordon.

Harold L. Lazar, MD, Elizabeth Oates, MD, Robert M. Beazley, MD

Dumbor L. Ngaage, MD, FRCS (C-Th), Michael E. Cowen, FRCS

Influence of On-Pump Versus Off-Pump Techniques and Completeness of Revascularization on Long-Term Survival After Coronary Artery Bypass Omar M. Lattouf,

Vinay Badhwar, MD, J. Scott Rankin, MD, Jeffrey P. Jacobs, MD, David M

Presentation transcript:

Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials∗ A.Michael Lincoff, MD, LeRoy A LeNarz, MD, George J Despotis, MD, Peter K Smith, MD, Joan E Booth, RN, Russell E Raymond, Shelly K Sapp, MS, Catherine F Cabot, MD, James E Tcheng, MD, Robert M Califf, MD, Mark B Effron, MD, Eric J Topol, MD The Annals of Thoracic Surgery Volume 70, Issue 2, Pages 516-526 (August 2000) DOI: 10.1016/S0003-4975(00)01343-6

Fig 1 Histogram chart of timing of initiation of coronary artery bypass grafting operation relative to discontinuation of abciximab administration. The Annals of Thoracic Surgery 2000 70, 516-526DOI: (10.1016/S0003-4975(00)01343-6)

Fig 2 Box-and-whisker plot of the volume of perioperative mediastinal- and chest-tube drainage in the placebo and abciximab groups. The box spans the interquartile range (25th to 75th percentiles), whereas the line within the box denotes the median. Whiskers extend from the 10th to the 90th percentiles. The diamond symbol represents the mean. The Annals of Thoracic Surgery 2000 70, 516-526DOI: (10.1016/S0003-4975(00)01343-6)

Fig 3 Number of transfused packed red blood cell or whole blood units in the placebo and abciximab groups. The Annals of Thoracic Surgery 2000 70, 516-526DOI: (10.1016/S0003-4975(00)01343-6)

Fig 4 Box-and-whisker plot of the maximum decrease in hemoglobin levels, adjusted for transfusion [14], in the placebo and abciximab groups. See Figure 2 for explanation of box-and-whisker plot. The Annals of Thoracic Surgery 2000 70, 516-526DOI: (10.1016/S0003-4975(00)01343-6)